167 related articles for article (PubMed ID: 25880115)
1. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Hanagasi HA
Mov Disord; 2015 Jun; 30(7):1009. PubMed ID: 25880115
[No Abstract] [Full Text] [Related]
2. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Hanagasi HA; Gurvit H; Unsalan P; Horozoglu H; Tuncer N; Feyzioglu A; Gunal DI; Yener GG; Cakmur R; Sahin HA; Emre M
Mov Disord; 2011 Aug; 26(10):1851-8. PubMed ID: 21500280
[TBL] [Abstract][Full Text] [Related]
3. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
Smith KM; Eyal E; Weintraub D;
JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
Zhang L; Zhang Z; Chen Y; Qin X; Zhou H; Zhang C; Sun H; Tang R; Zheng J; Yi L; Deng L; Li J
Int J Neuropsychopharmacol; 2013 Aug; 16(7):1529-37. PubMed ID: 23551956
[TBL] [Abstract][Full Text] [Related]
5. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
Hauser RA; Silver D; Choudhry A; Eyal E; Isaacson S;
Mov Disord; 2014 Jul; 29(8):1028-34. PubMed ID: 24919813
[TBL] [Abstract][Full Text] [Related]
6. Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial.
Schrempf W; Fauser M; Wienecke M; Brown S; Maaß A; Ossig C; Otto K; Brandt MD; Löhle M; Schwanebeck U; Graehlert X; Reichmann H; Storch A
Eur J Neurol; 2018 Apr; 25(4):672-679. PubMed ID: 29322594
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E; Stern MB
Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
[TBL] [Abstract][Full Text] [Related]
8. Effects of rasagiline on olfactory function in patients with Parkinson’s disease.
Haehner A; Hummel T; Wolz M; Klingelhöfer L; Fauser M; Storch A; Reichmann H
Mov Disord; 2013 Dec; 28(14):2023-7. PubMed ID: 24190245
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease.
Lim TT; Kluger BM; Rodriguez RL; Malaty IA; Palacio R; Ojo OO; Patel S; Gujrati Y; Nutter B; Swartz C; Hennessy C; Fernandez HH
Mov Disord; 2015 Nov; 30(13):1825-30. PubMed ID: 26769459
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial.
Jankovic J; Berkovich E; Eyal E; Tolosa E
Parkinsonism Relat Disord; 2014 Jun; 20(6):640-3. PubMed ID: 24637126
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
[TBL] [Abstract][Full Text] [Related]
12. Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia.
Frakey LL; Friedman JH
J Neuropsychiatry Clin Neurosci; 2017; 29(1):22-25. PubMed ID: 27829318
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
14. Rasagiline improves quality of life in patients with early Parkinson's disease.
Biglan KM; Schwid S; Eberly S; Blindauer K; Fahn S; Goren T; Kieburtz K; Oakes D; Plumb S; Siderowf A; Stern M; Shoulson I;
Mov Disord; 2006 May; 21(5):616-23. PubMed ID: 16450340
[TBL] [Abstract][Full Text] [Related]
15. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients.
Barone P; Santangelo G; Morgante L; Onofrj M; Meco G; Abbruzzese G; Bonuccelli U; Cossu G; Pezzoli G; Stanzione P; Lopiano L; Antonini A; Tinazzi M
Eur J Neurol; 2015 Aug; 22(8):1184-91. PubMed ID: 25962410
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
Olanow CW; Hauser RA; Jankovic J; Langston W; Lang A; Poewe W; Tolosa E; Stocchi F; Melamed E; Eyal E; Rascol O
Mov Disord; 2008 Nov; 23(15):2194-201. PubMed ID: 18932271
[TBL] [Abstract][Full Text] [Related]
17. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Pagonabarraga J; Rodríguez-Oroz MC
Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
[TBL] [Abstract][Full Text] [Related]
18. Rasagiline treatment effects on parkinsonian tremor.
Lew MF
Int J Neurosci; 2013 Dec; 123(12):859-65. PubMed ID: 23767986
[TBL] [Abstract][Full Text] [Related]
19. Rasagiline -- is there a place for this drug in managing Parkinson's disease?
Sharma JC
Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281
[No Abstract] [Full Text] [Related]
20. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
